Andrew P. Han

In addition to proving clinical utility, the startup will have to navigate issues of regulatory strategy, sequencing technology, and additional indications.

The EC also fined Grail €1,000, a symbolic amount and the first instance of imposing a fine on a company that was the target of a prematurely closed acquisition.

In its petitioner's brief, Illumina and Grail called the FTC an "unconstitutional agency" and ask the court to revers the commission's decision.

Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.

Spinout Magic LifeScience is leading commercialization of the molecular diagnostic technology, but the tests are popping up in other clinical scenarios, too.

Illumina plans to appeal the decision, seeking a resolution by late 2023 or early 2024, but now faces a third source of pressure to divest Grail.

Ex-CEO Roy Smythe is one of three people stepping down from the board. He will be replaced by Adam Taich, formerly executive VP of life sciences at SomaLogic.

Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.

In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.

The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts.